Literature DB >> 31363227

Targeting metabolism to regulate immune responses in autoimmunity and cancer.

Chirag H Patel1, Robert D Leone1, Maureen R Horton2, Jonathan D Powell3.   

Abstract

Metabolic programming is emerging as a critical mechanism to alter immune cell activation, differentiation and function. Targeting metabolism does not completely suppress or activate the immune system but selectively regulates immune responses. The different metabolic requirements of the diverse cells that constitute an immune response provide a unique opportunity to separate effector functions from regulatory functions. Likewise, cells can be metabolically reprogrammed to promote either their short-term effector functions or long-term memory capacity. Studies in the growing field of immunometabolism support a paradigm of 'cellular selectivity based on demand', in which generic inhibitors of ubiquitous metabolic processes selectively affect cells with the greatest metabolic demand and have few effects on other cells of the body. Targeting metabolism, rather than particular cell types or cytokines, in metabolically demanding processes such as autoimmunity, graft rejection, cancer and uncontrolled inflammation could lead to successful strategies in controlling the pathogenesis of these complex disorders.

Entities:  

Mesh:

Year:  2019        PMID: 31363227     DOI: 10.1038/s41573-019-0032-5

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  53 in total

1.  Metabolites as frailty biomarkers in older adults.

Authors:  Yiming Pan; Yun Li; Lina Ma
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-05       Impact factor: 11.205

Review 2.  Fueling the Revolution: Targeting Metabolism to Enhance Immunotherapy.

Authors:  Robert D Leone; Jonathan D Powell
Journal:  Cancer Immunol Res       Date:  2021-03       Impact factor: 11.151

Review 3.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29

4.  TLR-2-mediated metabolic reprogramming participates in polyene phosphatidylcholine-mediated inhibition of M1 macrophage polarization.

Authors:  Ting-Ting Feng; Xiao-Ying Yang; Shan-Shan Hao; Fen-Fen Sun; Ye Huang; Qi-Si Lin; Wei Pan
Journal:  Immunol Res       Date:  2020-02       Impact factor: 2.829

Review 5.  The plasticity of mRNA translation during cancer progression and therapy resistance.

Authors:  Lucilla Fabbri; Alina Chakraborty; Caroline Robert; Stéphan Vagner
Journal:  Nat Rev Cancer       Date:  2021-08-02       Impact factor: 60.716

Review 6.  Metabolism of immune cells in cancer.

Authors:  Robert D Leone; Jonathan D Powell
Journal:  Nat Rev Cancer       Date:  2020-07-06       Impact factor: 60.716

Review 7.  Functions of Thrombospondin-1 in the Tumor Microenvironment.

Authors:  Sukhbir Kaur; Steven M Bronson; Dipasmita Pal-Nath; Thomas W Miller; David R Soto-Pantoja; David D Roberts
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 6.208

8.  Plasma metabolomic profiling in patients with rheumatoid arthritis identifies biochemical features predictive of quantitative disease activity.

Authors:  John M Davis; Jaeyun Sung; Benjamin Hur; Vinod K Gupta; Harvey Huang; Kerry A Wright; Kenneth J Warrington; Veena Taneja
Journal:  Arthritis Res Ther       Date:  2021-06-08       Impact factor: 5.156

Review 9.  T cell metabolism in homeostasis and cancer immunity.

Authors:  Jun Wei; Wenting Zheng; Nicole M Chapman; Terrence L Geiger; Hongbo Chi
Journal:  Curr Opin Biotechnol       Date:  2021-03-04       Impact factor: 9.740

Review 10.  Nanomedicines for the treatment of rheumatoid arthritis: State of art and potential therapeutic strategies.

Authors:  Qin Wang; Xianyan Qin; Jiyu Fang; Xun Sun
Journal:  Acta Pharm Sin B       Date:  2021-03-12       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.